Acasti Grants of Stock Options to Newly Appointed Board Members

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX
VENTURE:APO), an emerging biopharmaceutical company focused on the research,
development and commercialization of new krill oil-based forms of omega-3
phospholipid therapies for the treatment and prevention of certain
cardiometabolic disorders, announces that following the election of its new
Board members at its Annual and Special Meeting held on June 19, 2014, the
Corporation granted to Messrs. Pierre Fitzgibbon and Adrian Montgomery,
respectively 75,000 options to purchase common shares under the Corporation's
stock option plan (the "Plan"). In addition, Mr. Jerald J. Wenker, who has
already received 37,500 options under the Plan when appointed special advisor to
the Board on December 19, 2013, has also been granted 37,500 options under the
Plan. Each option will vest gradually over a period of two years until June 26,
2016 and will be exercisable at a price of CAN$1.20 until June 26, 2017.


About Acasti Pharma Inc.


Acasti is an emerging biopharmaceutical company focused on the research,
development and commercialization of new krill oil-based forms of omega-3
phospholipid therapies for the treatment and prevention of certain
cardiometabolic disorders, in particular abnormalities in blood lipids, also
known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and
dinoflagellates), it is a major source of phospholipids and polyunsaturated
fatty acids ("PUFAs"), mainly eicosapentaenoic acid ("EPA") and docosahexaenoic
acid ("DHA"), which are two types of omega-3 fatty acids well known to be
beneficial for human health. CaPre(R), currently Acasti's only prescription drug
candidate, is a highly purified omega-3 phospholipid concentrate derived from
krill oil and is being developed to help prevent and treat hypertriglyceridemia,
which is a condition characterized by abnormally high levels of triglycerides in
the bloodstream. ONEMIA(R), a medical food and currently Acasti's only
commercialized product, is a purified omega-3 phospholipid concentrate derived
from krill oil with lower levels of phospholipids, EPA and DHA content than
CaPre(R).


Forward Looking Statements

Certain statements included in this press release may be considered
forward-looking information within the meaning of Canadian securities laws and
forward-looking statements within the meaning of U.S. federal securities laws,
both of which we refer to as forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of Acasti to be materially different
from historical results or from any future results expressed or implied by such
forward-looking statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider statements labeled
with the terms "believes," "belief," "expects," "intends," "anticipates,"
"will," or "plans" to be uncertain and forward-looking. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The forward-looking statements
contained herein are also subject generally to other risks and uncertainties
that are described from time to time in Acasti's public securities filings with
the Securities and Exchange Commission and the Canadian securities commissions.
Except as required by law, Acasti disclaims any intention or obligation to
update or revise any forward-looking statements.


Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due to risks
and uncertainties, including the risks and uncertainties identified by Acasti in
its public securities filings available at www.sedar.com and
www.sec.gov/edgar.shtml, actual events may differ materially from current
expectations. Except as required by law, Acasti disclaims any intention or
obligation to update or revise any forward-looking statements.


Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Acasti Pharma Inc.
Andre Godin, Interim President & CEO
Interim CFO
+1.450.687.2262
[e-mail]


Acasti Pharma Inc.
John Ripplinger
Investor Relations
+1.450.687.2262
[e-mail]
www.acastipharma.com